News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gemin X Biotechnologies Inc.'s Pan-Bcl-2 Antagonist GX15-070 Permits Rational Combination With Velcade In Mantle Cell Lymphoma


12/13/2006 10:33:26 AM

MONTREAL--(BUSINESS WIRE)--Gemin X Biotechnologies, Inc. announced today that results from a preclinical study of GX15-070 in mantle cell lymphoma (MCL) cell lines and ex vivo patient samples showed that GX15-070 and bortezomib (Velcade) exhibit synergistic activity, due to the ability of GX15-070 to potently antagonize the Bcl-2 family member, Mcl-1. Gemin X co-founder and chief scientific officer Gordon Shore, Ph.D., presented these data (Abstract 832) at the American Society of Hematology’s 48th Annual Meeting and Exposition, December 9-12 in Orlando, FL during an oral presentation titled “Obatoclax (GX15-070) Is a Potent Antagonist of Constitutive Mcl-1/Bak Interactions in Intact Mitochondrial Membrane and Synergizes with Bortezomib in Mantle Cell Lymphoma.”

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES